| Name | Title | Contact Details |
|---|
AcelRx Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain. The Company`s product candidates, DSUVIA™ (known as ARX-04 outside of the United States) and ZALVISO®, are designed to deliver sufentanil, a strong opioid analgesic, via a non-invasive, sublingual formulation in medical supervised settings. DSUVIA is designed to deliver sublingual tablets containing 30 mcg sufentanil via a disposable, pre-filled, single-dose applicator. The Phase 3 clinical program has completed and assessed the investigational product in the treatment of moderate-to-severe acute pain in patients who had undergone surgery or who presented to an emergency room with trauma or injury. In clinical studies, DSUVIA demonstrated reductions in pain intensity as early as 15-to-30 minutes after the start of dosing and the most common adverse events included nausea, headache, dizziness, and vomiting. A New Drug Application (NDA) was filed with the FDA in December 2016. ZALVISO is designed to deliver sublingual tablets containing 15 mcg sufentanil via a novel hand-held, pre-programmed, patient-controlled analgesia system. Three Phase 3 clinical trials have been completed in patients who had undergone major abdominal or orthopedic surgeries. A fourth study (IAP312) is underway to further evaluate the overall performance of the ZALVISO System in post-surgical patients. ZALVISO is currently approved by the European Commission for the management of acute moderate-to-severe post-operative pain in adult patients in a hospital setting, and is marketed by Grünenthal Group, AcelRx`s licensee in Europe and Australia. In the United States and other geographies, ZALVISO remains an investigational product.
There is a health crisis in America. In every community, 1 in 4 people live with mental health disorders and the demand for behavioral health services has been amplified in the wake of COVID-19. Social isolation, economic downturns, and tense conditions have amplified the effects of depression, anxiety, and substance use disorder.
Rochester Electro-Medical is a Tampa, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Health Information Designs is a Auburn, AL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Our mission at Aware Recovery Care is to help people affected by addiction “Recover Where You Live”. At Aware Recovery Care, we transform the home into a treatment center, delivering innovative addiction services to those in need, where they live. We treat addiction like a chronic illness, and our groundbreaking and evidence-based treatment approach provides comprehensive care from a multidisciplinary team of clinicians led by an Addiction Psychiatrist, a Family Systems Therapist, and a Registered Nurse. And with the help of a Certified Recovery Advisor, we help our clients learn new skills and daily habits required to maintain abstinence, while remaining amongst family and friends in their community, thereby avoiding the oftentimes difficult return home from traditional treatment options. Privacy and anonymity are respected, and dignity is preserved as we provide care that is discreet and effective. Authenticity, empathy, purpose, and thoughtfulness are at the heart of everything we do, and we seek deeply passionate people who are committed to immersing themselves in our mission. Those who are up for the task will be rewarded with rewarding mission-oriented workdays, and a voice at the table helping to build a transformational business entering a hypergrowth stage. Come join us as we create a preferred destination for top talent in the Healthcare community and set a new standard for the treatment of SUD. In early 2021, Aware received an investment by Health Enterprise Partners (HEP), a growth equity firm whose investors include some of the largest health systems and health insurance plans in the United States. Aware now operates in nine states (CT, MA, RI, NH, ME, VA, OH, IN, FL) and is poised for hyper-growth and national expansion in partnership with established national and regional payors, employers, and other stakeholders.